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Letter to the Editor
The ultimate goal of disease management: improved quality 
of life by patient centric care
Guus Schrijvers recently proposed a new definition 
of disease management: disease management con-
sists of a group of coherent interventions designed 
to prevent or manage one or more chronic condi-
tions using a systematic, multidisciplinary approach 
and potentially employing multiple treatment modali-
ties. The goal of disease management is to identify 
persons at risk for one or more chronic conditions, 
to  promote  self-management  by  patients  and  to 
address the illnesses or conditions with maximum 
clinical outcome, effectiveness and efficiency regard-
less of treatment setting(s) or typical reimbursement 
patterns.
Although this definition is very broad and comprehen-
sive, I do miss two key aspects: 1) Evidence-based 
practice  guidelines  and  2)  Coordinated  health  care 
interventions, according to the Disease Management 
Association of America (DMAA) [1].
Guidelines are helpful to standardize the interventions 
of similar providers, and coordination is necessary to 
bridge and link these interventions into a chain of care. 
A  disease  manager  ‘supervises’  the  integrated  care 
continuum  and  patients’  interactions  and  responses 
and she monitors the fit between the continuum and 
the disease course.
A  more  principle  aspect,  that  I  think  is  much  more 
important, is the goal of disease management. In my 
opinion, the goal of disease management is the trig-
ger for patient participation and compliance, namely, 
to improve patient quality of life measured in clinical 
outcomes, self reported health status or functional sta-
tus, etc., to delay and reduce comorbidity and (acute) 
complications.
The meso level
The aspect ‘manage one or more chronic conditions’ 
is an issue on the meso-level. Disease management, 
with its roots in the pharmaceutical industry [2], has 
traditionally targeted persons with a single (chronic) 
disease to increase compliance for a drug related to 
a disease.
Now  we  know  that  chronic  diseases  are  not  stand   
alone conditions but are often associated with comor-
bidities and other (non-related) chronical diseases [3].
The challenge for the future is to pioneer with multi 
integrated care systems to meet both economies of 
scale and to serve the patient’s comfort and medical 
needs.
Enthoven  [4]  and  Porter  [5]  have  discussed  this. 
Enthoven [6], the theorist behind ‘managed competi-
tion’, shows that the types of care coordination seen 
in large multi-specialty groups are necessary for care   
of  the  chronically  ill.  We  need  “efficient  integrated 
healthcare systems, with teams of professionals, who 
provide  coordinated,  efficient,  evidence-based  care, 
supported by state-of-the-art information technology” 
[7, p. 420]. These organizations provide complete care: 
from the doctor’s office, to the hospital, to home care. 
Competition at the ‘disease’ level, or at the individual 
doctor or provider level (as advocated by Porter and 
Olmsted Teisberg [5]), is likely to be counter-productive 
and ineffective.
Porter and Olmsted Teisberg [5] believe that there is lit-
tle benefit in broad provider networks, but instead pro-
viders should try to be excellent and unique regionally 
and nationally. They also suggest that providers should 
consider  one  bill  and  organize  around  one  practice 
area for each disease state. They think that providers 
need to be distinctive and have a market niche or brand 
strategy that’s comparable to other businesses in other 
industries, which means delivering added value to cus-
tomers as compared to competitors.
The macro level
An important aspect on the macro level is managed 
competition.  Porter  is  pretty  dismissive  of  managed 
competition and Enthoven supports managed competi-
tion. However, all markets are bound by regulation and 
market players are acting out their rational incentives 
within  that  regulatory  framework.  If  the  government 
uses regulation and subsidies to change the market, 
one way or another, this is ‘managing’ competition. And 
governments do this in every market: either by deliber-
ate action or by inaction. The implementation of disease 
management will vary with the degree of regulation.
The  way  of  implementing  disease  management  will 
vary depending on the level of (government) regula-
tion in a country. In Germany, disease management 
was [8–10] introduced by law (in 2002) with financial   2
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incentives for health insurers; the ‘top down’ way of 
doing it. Insured people who join disease management 
programs  (DMP)  are  labeled  ‘chronically  ill’  for  the 
purpose of the risk structure compensation scheme, 
and spending is calculated separately for them. Health 
insurers with a high share of DMP participants receive 
higher compensation from the scheme.
In the Netherlands, it was the other way around. Here, 
DM was developed by cooperation among groups of 
providers, so the bottom up way [11]. Providers search 
for alliances to build up care for the chronically ill, net-
working in a region with local partners, initiated by the 
hospital.
So, a DM-program is dependant on the market struc-
ture and system reform.
Conclusion
In  my  opinion,  the  last  part  of  Professor  Schrijvers’ 
definition:  “…  regardless  of  treatment  setting(s)  or 
typical  reimbursement  patterns”  is  not  realistic  and   
feasible. Reimbursement, payment, financial incentives 
(like  functional  finance  in  the  Netherlands  [12])  and 
local settings are indeed an issue and they determine 
a significant part of the structure of the DM programs 
on the meso and macro level and even more on the 
micro level (for example, how many disease managers 
there are in a region)! So we cannot ignore them! It is 
fighting organizational boundaries and challenging the 
functional pricing to provide with all network parties in 
the Netherlands: patient centric care!
The needs of the patient, the ‘demand side’, are of 
course the starting point for creating DMPs. But the 
market structure, the ‘supply side’, is the second point 
and the limiting factor for creating the ultimate in dis-
ease management: improved quality of life by patient 
centric care.
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